biostudies-literatureUnknown8Moady GHeart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare deCardiac failure reviewe33https://www.ebi.ac.uk/biostudies/studies/S-EPMC9820067biostudies-literatureVentricular Assist Devices: Challenges of the One-device Era.PMC9820067Moady GBen-Avraham BAtar SBen-Gal TfalseVentricular Assist Devices: Challenges of the One-device Era.Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device - the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare de2022-01-01T00:00:00Z2022 Jan2025-04-04T14:29:54.534Z2025-04-04T14:29:54.534ZS-EPMC98200673664464810.15420/cfr.2022.01